Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen
Source:Biogen.com
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Related Articles
Over 55,000 pounds of blueberries recalled for risk of potentially fatal listeria contamination - NBC News
More than 55,000 pounds of frozen blueberries have been recalled due to the risk for a potentially …
Microsoft: The Earnings Drawdown Is A Gift (Rating Upgrade) (NASDAQ:MSFT) - Seeking Alpha
Microsoft delivered robust Q2 FY2026 results, with revenue up 16.8% and EPS up 24% YoY, beating …
Nvidia Looks For Boost From Q4 Earnings, GTC News - Investor's Business Daily
Nvidia has two catalysts ahead: earnings next week and its upcoming GTC conference.
Tesla Stock (NASDAQ:TSLA) Slips Despite New EV Rebate Plan…In California - TipRanks
One of the biggest things that hit electric vehicle giant Tesla ($TSLA) hard in the last year or so …